e-Drug3D

732

EPOPROSTENOL


INN
EPOPROSTENOL

cas 35121-78-9
CLASS

BLOOD
PLATELET AGGREGATION INHIBITOR
ANTITHROMBOTIC
ANTIHYPERTENSIVE
PROSTANOID VASODILATATOR

ROUTE (list)

INJECTION

ATC code

B01AC09

PK parameters

t1/2 0.1 HOUR

Target

-

DrugCentral

Prostaglandin E2 receptor EP1 subtype UNIPROT P34995 PTGER1

Prostacyclin receptor UNIPROT P43119 PTGIR

Download SDF file 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid

Formula:
C20H32O5

Calculated chemical properties:

MW 351.45
NB_atoms 25
XLogP 2.07
PSA 84.845
NB_HD 2
NB_HA 5
fsp3 0.75
Lipinski(0=no;1=yes) 1

FDA
NDA 020444 (pdf not found) INN (EPOPROSTENOL SODIUM) FLOLAN (GLAXOSMITHKLINE LLC) APPROVAL= AP YEAR= 1995
NDA 022260 (pdf not found) INN (EPOPROSTENOL SODIUM) VELETRI (ACTELION) APPROVAL= AP YEAR= 2008
NDA 078396 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (MEITHEAL) APPROVAL= AP YEAR= 2008
NDA 210473 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (SUN PHARM) APPROVAL= AP YEAR= 2021
NDA 213913 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (MYLAN) APPROVAL= AP YEAR= 2024
NDA 219237 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (GLAND PHARMA LIMITED) APPROVAL= TA YEAR= 2025

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL